Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) insider Gary Hattersley sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total transaction of $709,000.00. Following the sale, the insider owned 100,000 shares in the company, valued at $709,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Nuvation Bio Stock Up 1.3%
Nuvation Bio stock opened at $6.92 on Friday. The company has a 50 day moving average of $6.11 and a 200-day moving average of $5.31. The company has a quick ratio of 8.14, a current ratio of 8.37 and a debt-to-equity ratio of 0.96. Nuvation Bio Inc. has a twelve month low of $2.76 and a twelve month high of $9.75. The stock has a market capitalization of $2.43 billion, a PE ratio of -15.73 and a beta of 1.52.
Nuvation Bio (NYSE:NUVB – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The company had revenue of $31.69 million for the quarter, compared to analyst estimates of $27.03 million. Nuvation Bio had a negative return on equity of 46.59% and a negative net margin of 88.18%. On average, equities research analysts anticipate that Nuvation Bio Inc. will post -0.34 EPS for the current fiscal year.
Institutional Investors Weigh In On Nuvation Bio
Analyst Upgrades and Downgrades
NUVB has been the topic of several recent research reports. Cantor Fitzgerald began coverage on Nuvation Bio in a research note on Friday. They issued an “overweight” rating on the stock. JPMorgan Chase & Co. began coverage on Nuvation Bio in a report on Tuesday, August 18th. They set an “overweight” rating and a $13.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research report on Friday, July 17th. Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a research report on Wednesday, June 10th. Finally, B. Riley Financial restated a “buy” rating on shares of Nuvation Bio in a research note on Friday, August 7th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $13.00.
View Our Latest Research Report on Nuvation Bio
About Nuvation Bio
Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.
The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.
Featured Articles
- Five stocks we like better than Nuvation Bio
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
